# Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Study · id `cardio:ct-nct05027074` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05027074](<https://clinicaltrials.gov/study/NCT05027074>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05027074

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.

## Technical summary

Registry record NCT05027074. Randomized; quadruple masking; primary purpose prevention. Start 2021-09-17 (actual); primary completion 2024-10-30 (actual). Results posted on 2025-11-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 506 participants (enrolled count; ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Started: 2021-09-17 (actual) (ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Primary completion: 2024-10-30 (actual) (ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Completion: 2025-02-13 (actual) (ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Results first posted: 2025-11-17 (ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Czechia; Germany; Greece; Italy; Portugal; Puerto Rico; Romania; Russia; Sweden (ClinicalTrials.gov record NCT05027074, source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05027074-2026-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
- Condition: End-Stage Renal Disease
- Condition: End-Stage Kidney Disease
- Condition: Kidney Failure, Chronic
- Intervention (Drug): MK-2060
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 14c6cb032b53b3310165d419f2bf4783b826dd894fd83392a0fd24a58b375431
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
